GlassScriptPhysician profile
Donna Hayes
NPI 1225045651
$6,343.85
in general payments reported to CMS, 2019-2025
37 companies · $15.09 in 2025
The $15.09 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,371 · 2020: $532 · 2021: $432 · 2022: $897 · 2023: $1,058 · 2024: $39.49 · 2025: $15.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $563 · Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $562.58 |
| Food and Beverage | $550.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $3,157.00 | 2019 | |
| Treace Medical Concepts, INC. | $604.15 | 2023 | |
| Lilly USA, LLC | $289.52 | 2020-2022 | |
| Abbvie INC. | $276.29 | 2022-2023 | |
| Pfizer INC. | $250.47 | 2020-2023 | |
| Novo Nordisk INC | $246.84 | 2020-2023 | Rybelsus, Ozempic |
| Next Science LLC | $170.54 | 2022-2024 | Blastx, Xperience, Surgx |
| Merck Sharp & Dohme LLC | $111.45 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.23 | 2020-2023 | Gattex |
| E.R. Squibb & Sons, L.L.C. | $106.82 | 2019 | |
| Amgen INC. | $105.04 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.04 | 2020-2023 | Xifaxan |
| Organogenesis INC. | $101.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.14 | 2021-2023 | Jardiance |
| Nestle Healthcare Nutrition INC. | $77.59 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.